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In this review the surgery of colorectal liver metastases is discussed. It has long been known that liver surgery can cure metastatic
colorectal cancer although in only a small proportion of the population with the disease. However with better understanding of the
natural history of the condition and advances in technique more patients can have safe, potentially curative surgery. The
multidiscipline management of patients with effective chemotherapy has led to more patients benefiting from surgery after reducing
the size of the metastases and allowing operation on patients who were previously inoperable. Chemotherapy also improves at least
the medium-term outcome in those who are operable at the outset. Minimally invasive techniques have been developed so that
major hepatectomy may be accomplished in up to half of such cases with a very short hospital stay and limited interference with
quality of life. Lastly, using portal vein embolisation to cause hypertrophy of the future liver remnant and on occasions combining it
with staged liver resection allows potentially curative surgery on patients who previously could not have survived resection. These
developments have led to more patients being cured of advanced colorectal cancer.
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No randomised trial has ever been performed to show that patients
with colorectal liver metastasis from cancer can be cured by liver
surgery. That being said the abundance of clinical evidence
suggests that cure may often follow surgical treatment. Our
systematic review (Simmonds et al, 2006) shows that around 30%
of patients will achieve 5-year survival after liver resection and,
although relapse still occurs between 5 and 10 years, 20% of the
population will still be alive at that point. Further relapse seems
not to occur after 10 years (Tomlinson et al, 2007; Rees et al, 2008).
Accepting the highly selective nature of the population, this
impressive cancer control is not observed in patients who do not
have resectional surgery, even those with indolent disease (Goslin
et al, 1982). Indeed a recent epidemiological study in the UK
showed that the outlook of patients with colorectal liver metastases
who went on to resection was no different than in patients in stage-
III (Dukes’s C) (Morris et al, 2009).
PROGNOSTIC FACTORS
The prognostic factors are largely established; patients with four or
more metastases have a worse outlook as do patients with larger
metastases and where the primary tumour is poorly differentiated
or has lymph node involvement. Extra-hepatic disease and a high
CEA are also adverse features and after operation a positive
resection margin has prognostic significance. These factors emerge
from most of the studies that have been undertaken (Simmonds
et al, 2006; Rees et al, 2008). At present liver resection is the only
modality shown to convincingly cure liver metastasis, although
ablative treatments are currently showing some promise (Mulier
et al, 2008).
INDICATIONS AND RESECTABILITY
Central to any discussion of techniques of liver resection are the
linked issues of indications and resectability. It is clear from
experience supported by the evidence cited above (Simmonds et al,
2006; Rees et al, 2008) that excellent results can be obtained with
liver resection by employing highly selective criteria. Most liver
surgery units though will offer surgery on a range of presentations
accepting that the outlook in terms of cure will vary. Further,
indications have changed greatly in recent years as it has been
shown that good results can be achieved in patients previously
thought incurable with effective chemotherapy (Adam et al, 2009).
The current standard approach is that resection is indicated
provided the disease can be resected surgically (including
resectable extra hepatic disease), with sufficient residual liver to
enable the patient to survive while the liver regenerates (Simmonds
et al, 2006; Rees et al, 2008; Adam et al, 2009). Indeed the unique
regenerative power of the liver allows major hepatectomies to
be performed repeatedly, with the liver regenerating between
operations (Wicherts et al, 2008).
Determining resectability requires detailed knowledge of liver
anatomy. Surprisingly, liver anatomy was not widely understood
until the mid twentieth century. Even in the most detailed
anatomical text books originating in the English-speaking world
the liver appears little more than a box into which vessels enter
and leave but without any internal anatomy. Couinaud et al (1957)
in France first described the segmental anatomy of the liver, which
is essential to modern liver surgery. In essence the liver has four
sectors and eight segments (Figure 1). Each segment has a portal
vein, hepatic artery, and bile duct and hepatic vein branches. This
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the other segments of the liver uncompromised.
Resectability is much debated by liver surgeons, but in essence
the current consensus would be that after resection the patient
should have at least two liver segments remaining and in continuity.
The remnant must be supplied by a portal vein and a hepatic artery,
and there must be a bile duct, which is or can be made to be in
continuity with the gut. In addition one of the three main hepatic
veins should remain. Furthermore, the remnant should be around
20–25% of the total functional liver volume (Hemming et al, 2003).
This remaining liver volume is calculated on the basis of the pre-
operative axial imaging and is termed the future liver remnant
(FLR). There are some caveats. Survival with an FLR of 25%
requires the residual liver to be free from disease such as cirrhosis,
steatosis and nowadays, most importantly, chemotherapy-
associated steatohepatitis (CASH) (Fong and Bentrem, 2006).
Patients with a diseased liver require a larger remnant to survive.
However, an inadequate FLR is also not now an absolute contra-
indication for surgery. Techniques are available to ‘grow’ liver to
facilitate resection and these are considered further below.
USE OF CYTOTOXIC CHEMOTHERAPY
Surgical treatment of liver metastasis has undoubtedly been
transformed by cytotoxic chemotherapy and more recently
biological agents. The first indications of the versatility of
chemotherapy came with the observation that the combination
of fluoropyrimidine and oxaliplatin could convert patients with
irresectable disease to resectable with a reasonable degree of
frequency (Giacchetti et al, 1999). Furthermore, the outcome after
resection in such patients was no different from patients who were
up-front resectable. This observation has been repeated many
times and is now widely accepted. Indeed there is very good
correlation between the resectability rate in patients considered
inoperable at presentation and the response rate to the therapeutic
schedule (Folprecht et al, 2005). Indeed, conversion to operability
is now being used as a surrogate end point in trials on the
treatment of advanced colorectal cancer. This is a sensible
approach; resectability and 5-year survival are closely related
(Folprecht et al, 2005; Simmonds et al, 2006). The results of the
recently published EPOC trial (Nordlinger et al, 2008) adds
evidence to support of the routine use of chemotherapy in all
patients by showing an 8% improvement in PFS at 3 years who
were operable at the outset.
LIVER IMAGING
Successful metastasis surgery requires accurate assessment of the
anatomical localisation of the disease both within and without the
liver. Contrast CT of the chest, abdomen and pelvis is commonly
used as the initial imaging modality, followed by contrast MRI for
those which appear to be resectable. MRI probably has higher
levels of sensitivity for small metastases and clearly it is essential
that all the disease within the liver is adequately documented
(Rappeport and Loft, 2007). Various systems are available to
produce three-dimensional reconstructions of the liver as well as
volumetry to assess the FLR. For the most part, however, surgeons
become used to integrating the 2D images to a three-dimensional
surgical plan. What is essential is that the relationship of the
metastatic disease to the crucial structures in the liver is
appreciated. Surgeons generally prefer good margins around vital
structures, preferably 10mm or more. However, it has been known
for a while that any margin at all will actually suffice as most liver
metastases are ‘pushing’ rather than infiltrative (de Haas et al,
2008).
PET/CT is commonly used for patients with liver metastases
being considered for liver resection, but its role is probably to
detect extra-hepatic disease (Finkelstein et al, 2008). A randomised
trial shows that the incidence of a futile laparotomy (incomplete
removal of tumour or disease-free survival of less than 6 months)
is reduced from 45 to 28% without significantly adversely affecting
the disease-free or overall survival (Ruers et al, 2009). Laparoscopy
with or without intra-operative ultrasound has also been used in
preoperative assessment although in recent years has been used
selectively (Pilkington et al, 2007). This is partly related to the
morbidity associated with the procedure (4% major complication
rate) and the fact that peritoneal disease, often detected at
laparoscopy, may also be detected non-invasively by CT-PET.
SURGICAL MARGINS AND THE ‘DISAPPEARING’
METASTASIS
Effective chemotherapy converts inoperable patients to operable
ones, principally because tumour shrinkage produces margins on
vital structures. There is much debate about how to manage a
patient who has responded well or even completely to chemo-
therapy. Is the margin that is produced by shrinkage of the
metastases really tumour-free? Experience in fact suggests that it is
(de Haas et al, 2008), and this is different from other malignancies
such as breast cancer. The next question is what to do about the
disappearing lesion that can no longer be resolved on imaging.
Here the situation is more difficult. Evidence suggests that most
such lesions are not completely ‘sterilised’ and will grow again if
left untreated (Benoist et al, 2006). For this reason it is optimal to
remove all the liver that has ever contained a tumour. However,
sometimes this is undesirable or even impossible. These circum-
stances increasingly involve a wait-and-see approach being
adopted. The ‘missing’ lesions are looked for on serial imaging
and if they reappear re-resection or other ablation techniques may
be used.
OPERATIVE TECHNIQUE
The operative technique for metastecetomy has become increas-
ingly refined, and with this refinement has come safety. The best









Figure 1 The segments of the liver as first described by Couinaud et al
(1957).
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showed that in patients with up-front resectable disease and four
metastases or less the 30-day mortality from any major liver
resection is less than 1% (Nordlinger et al, 2008). This is lower
than for instance the operative mortality associated with colorectal
resection (Guillou et al, 2005). The principal feature in reducing
complications and mortality is almost certainly lowering blood
loss, although most data actually come from studies of hepato-
cellular cancer (Pamecha et al, 2009). It may not be just directly
due to the effects of blood loss or lack of its effect on short-term
outcome, but possibly because precise careful surgery associated
with low blood loss is also good surgery. Using modern techniques
most patients having a straightforward liver resection will not
require blood transfusion and cross-matching of blood is now no
longer routine.
It is important to realise that liver surgery is a team approach
and the anaesthetist is a crucial member of the team. Blood flow
into the liver can be easily controlled by occluding the inflow in the
free edge of the lesser omentum where the portal vein and hepatic
arteries run. Therefore bleeding from the liver with a clamp on the
inflow can only be from the hepatic veins, which are in continuity
with the vena cava without any intervening valves. Thus if the
central venous pressure and the pressure in the vena cava is low
and the liver is mobilised and brought up into the wound even
then an opening in a hepatic vein should not result in bleeding
(Wang et al, 2006). This can be shown to be so in practice. If a
large vein is opened inadvertently, very often the blood simply
oscillates in the open vein because the pressure gradient between
the vein and the air is essentially zero. This allows, essentially,
bloodless surgery. Very often complete in-flow occlusion is not
actually needed and certainly not to the FLR. For instance if a right
hepatectomy is being performed it is normal to divide the inflow
to the right liver either extra-hepatically or intra-hepatically
(Cresswell et al, 2009). This has the effect of depriving the right
liver of most of its blood supply as there is very little crossover.
Once the inflow has been dealt with it is usual to divide at
least one major hepatic vein. These major structures can be
divided by hand suturing but in recent years the vast majority of
liver surgeons have taken to using surgical staplers. These devices
make the division of vascular pedicles quick and safe and although
they are associated with increased cost they greatly reduce
operating time.
The principle problem with operating on the liver is that it is a
solid parenchymal organ. Its division is technically challenging
and it is this fact that has made liver surgery the province of
relatively small numbers of specialist surgeons. Numerous
techniques are available to divide the parenchyma. Historically
liver resections were performed by what was appropriately called a
finger fracture technique, whereby the liver was literally crushed
between fingers (Pamecha et al, 2009). This left some of the more
robust vascular structures intact and these could be controlled and
divided by other means. However this does not control small
vessels or fragile hepatic veins from which most bleeding occurs.
This brutal and imprecise technique was replaced and developed
by a variety of crushing and clamping techniques using simple
surgical instruments. These methods are still used although by
observation most surgeons use one of the newer technologies.
Indeed most surgeons would not contemplate operating on the
liver now without technically advanced instrumentation. There are
a large number of instruments (Pamecha et al, 2009), all of which
have utility to some degree, which are marketed by various
manufacturers. The issue that all of this instrumentation tries to
deal with is the fact that the solid structure of the liver is
permeated with blood vessels and bile ducts of varying size, which
require to be closed to prevent bleeding or bile leakage. Personal
observation suggests the most common of the technologies
used by liver surgeons to be the ultrasound aspirator and argon
diathermy. The ultrasound aspirator uses ultrasound to destroy
the parenchymal component of the liver but with insufficient
energy to completely destroy the fibrous vascular structure. With
experience it is possible to isolate the smallest vessels within the
liver substance and deal with these by other means. However, the
instrument requires experience to use; although there is a degree of
selection for blood vessels, the energy will indeed rupture these if
used without care. The precision of dissection that this instrument
allows is much greater than can be achieved by mechanical means
alone. In addition when operating close to tumour the instrument
itself produces a margin so that resection margins are often better
than might appear on histological assessment (Konopke et al,
2008).
Argon diathermy is used to seal blood vessels. Argon is an inert
gas and creating argon gas plasma enables high temperatures to be
delivered to the tissues, sealing blood vessels but not causing
charring as would be the case if air or another reactive gas were
used (Primrose, 2002).
Although this combination of ultrasound aspirator and argon
diathermy is perhaps the most commonly used combination, there
is virtually an endless array of instruments now available, which
some surgeons find satisfactory. The Hydrojet Cutter is a fine high-
pressure jet of water, which essentially performs the same function
as the ultrasound aspirator. Ultrasound shears can be used to
divide the liver and seal the associated vessels. Diathermy/
radiofrequency devices are also favoured by some surgeons.
However as is usually the case with any form of surgery, the
surgeon’s skill and technique is more important than the
instrumentation. This is borne out in a Systematic Review,
which shows little difference between the various techniques
save that the crush-clamp technique is most economical (Pamecha
et al, 2009).
MINIMALLY INVASIVE SURGERY
In the last few years there has been a great deal of interest in
minimally invasive or laparoscopic liver surgery. The liver may not
at first sight seem an ideal situation for laparoscopic surgery given
that the resection specimen may be quite a significant size.
There is however some features, which make laparoscopic liver
surgery worth serious consideration. Most cases involve resection
without reconstruction and this certainly is the case with the vast
majority of resections for metastases. In laparoscopic surgery it is
reconstructing bowel or blood vessels with a necessity of
intra-corporeal suturing, which can make the procedure techni-
cally very challenging. Further, although the liver specimen can be
large, it can be distorted relatively easily when placed within a
suitable laparoscopic extraction bag. Even a right hepatectomy
specimen can be removed through a relatively small low-
abdominal incision.
To perform laparoscopic liver surgery a surgeon requires to be
extremely experienced in managing the conventional open case in
addition to having a high level of laparoscopic skill. Essentially the
same technique that is used for open resection is adapted for the
laparoscopic procedure and all of the technology used in open
cases has been adapted for laparoscopic use. Control of vascular
inflow to the liver is routine. The intra abdominal pressure
associated with laparoscopy is certainly helpful in that it reduces
bleeding from the hepatic veins. Unlike the normal open
procedure the hepatic veins are divided last. Parenchymal
transection is performed using the same instrumentation as for
the open approach, although in our experience ultrasound shears
are easier to use laparoscopically.
Laparoscopic liver resection is in general more technically
demanding than the open approach. As such, complex resections
around the centre of the liver are still best performed open as
shown in Figure 2. The simplest areas to deal with laparoscopically
are the most peripheral, segments 2 and 3, and 5 and 6 are ideal.
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resections are performed laparoscopically, with results that in the
short term seem no different than open procedures in terms of
resection margins and early tumour recurrence (Nguyen et al,
2009; Abu Hilal et al, 2010). Virtually all left sections (removal of
segments 2 and 3) are performed laparoscopically (Abu Hilal and
Pearce, 2008). These results are consistent with experience in other
centres (Nguyen et al, 2009).
Laparoscopic liver surgery is unlikely to produce any significant
benefit to patients in terms of cancer control. Indeed care must be
exercised in adopting the technique as any reduction in cancer
cure rate cannot be offset by the advantages. The main advantage
for the patient is a much shorter hospital stay (Abu Hilal et al,
2010). With most surgery for metastatic disease the factor limiting
patient’s discharge is the large abdominal wound and consequent
pain and immobility. Removing this factor in practice allows early
discharge. If it can be shown that the oncological outcomes are the
same (or better) then this is an advantage to the patient and also to
the service.
Even when right hepatectomies are performed it is normally for
lesions peripherally in the liver rather than centrally. This will
undoubtedly change with more experience. Nonetheless, in the
long term problems remain in dealing with the difficult situations,
which involve intra-corporeal suturing. While this can clearly be
accomplished, it is much more difficult than in the open case. In
addition the angles may be unnatural for the operating surgeon by
virtue of the port position, long straight instruments and lack of
wrist movement at the tips. Robotic surgery may offer an advance
here as the more natural hand movements can make some
procedures possible that would be difficult laparoscopically.
However, there is currently little published evidence to determine
whether this will become a standard approach in minimally
invasive liver resection.
TECHNIQUES TO INCREASE THE FLR
In recent years surgeons have examined ways of treating patients
who would have an inadequate FLR after resection. It is known
that if a liver resection leaves 25% or less of functioning liver the
complication rate and the peri-operative mortality is high.
In addition use of cytotoxic chemotherapy, which is known to
cause significant liver injury, increases the complication rate
after surgery (Nordlinger et al, 2008). It is now accepted that
chemotherapy decreases the patient’s capacity to withstand very
large resections (Vauthey et al, 2006). As most patients now come
to liver surgery having been treated with chemotherapy, this is
clearly an important issue.
There are two techniques increasingly used to treat such
patients: first a staged resection and second portal vein embolisa-
tion (Figures 3 and 4). In the staged resection, one lobe of the liver
is usually cleared of tumour or resected initially. Then after a
period of recovery, usually around a month, the contralateral side
is dealt with. In this time, regeneration and recovery of the initially
Figure 2 The areas of the liver most amenable to treatment by
laparoscopic surgery. The grey area is accessible but those in white (mostly
around the hepatic veins and the vena cava) much less so.
Figure 3 The technique of right portal vein embolisation. The catheter in introduced percutaneously into the main portal vein by the ipsilateral
approach (A). The right portal vein is then ablated by embolising with a combination of tissue glue, microspheres and coils (B).
Figure 4 The liver at operation 6 weeks after portal vein embolisation.
There is a clear line of demarcation in the line of the gall bladder and the
inferior vena cava. The right liver is atrophic and shows signs of
arterialisation.
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embolisation. This was first described by Makuuchi (Makuuchi
et al, 1990) in the context of hilar cholangiocarcinoma. It relies on
the fact that if the portal vein to a lobe of liver is ablated, then there
is atrophy of the corresponding liver and hypertrophy of the
remainder. Essentially portal vein embolisation is used to cause
atrophy of the right liver and hence cause hypertrophy in the left.
If needed the branches to segment-4 of the liver can also be
ablated, which leads to most hypertrophy occurring in segments 1,
2 and 3 (Hemming et al, 2003). This greatly increases the number
of resections, which can be performed with safety. Surprisingly and
unlike hepatic artery embolisation, portal vein embolisation
produces virtually no symptoms in the patient. It therefore can
be performed as a day case or with a very short stay. There is
usually no significant disturbance to biochemically measured liver
function and complications from the procedure appear to be very
rare. Studies show, that in general terms the FLR volume can be
increased by 30% or more (Hemming et al, 2003). Applying this
technique can make the difference between an unsafe or
impossible resection and one that can be accomplished with little
morbidity.
In practice staged resection and portal vein embolisation are
used together. A common scenario would be the clearance of
metastases from the left liver followed by a right portal vein
embolisation and then a second procedure to remove the right
liver. Although the long-term utility of such procedures is not
known, results in the medium term suggest that assuming
clearance can be achieved they are no different from any other
liver resection (Pamecha et al, 2008).
One area of innovation that has not become established is the
ante-situm resection. In this procedure transplantation techniques
are used to disconnect the liver from the vena cava. In addition the
entire vascular pedicle to the liver can also be divided but in
general terms this is inadvisable and unnecessary. The technique is
used for disease around the hepatic veins. However the procedure
is difficult, highly morbid and tumour outcomes are not
particularly good. In fact it is likely that development of techniques
to operate on the liver in situ that the ante-situm approach is
actually seldom if ever required (Oldhafer et al, 2001).
‘ADJUVANT’ SURGERY
The future of liver surgery for metastasis is likely to undergo a
paradigm shift in the near future. At present the mantra for
metastasis surgery is that unless a complete resection can be
performed it should not be. It is now probably time to revaluate this
approach. There are several reasons for this. First because of the
advances in chemotherapy, colorectal cancer is beginning to
resemble ovarian cancer where it is accepted that maximum
surgical debulking has survival benefit (Tangjitgamol et al, 2009).
In colorectal cancer it remains unproven whether maximum
debulking surgery for metastatic disease is of benefit, but it seems
likely. Oncologists have known for years that good response rates
correlate with survival even when the best outcome is only a partial
response (Giacchetti et al, 1999; Folprecht et al,2 0 0 5 ) .M a x i m u m
surgical debulking can remove most of the disease and with a
mortality that is no different from chemotherapy (Nordlinger et al,
2008). More recently the CLOCC trial, a randomised trial of ablation
and chemotherapy vs chemotherapy alone, showed a survival
benefit for ablation, even though the trial recruited extremely badly
and had to be concluded as a randomised phase-II trial (Ruers et al,
2008). Thus the way forward seems to be in favour of a radical
surgical approach in patients who respond to chemotherapy
irrespective of whether the disease is completely removable. It is
important, however, that this new concept is tested in a randomised
trial as however safe the surgery it is likely that patients will spend
some of their survival recovering from the operation. Such a trial is
currently being developed within the UK NCRI.
CONCLUDING REMARKS
In conclusion, surgery for colorectal liver metastases is now well
established. It has produced very significant benefits for patients,
commonly now in combination with chemotherapy. Surgery itself
may be nearing its technical limits but is likely to be applied to
more patients due to success of other strategies, particularly newer
chemotherapies and targeted therapies. What is most important
for a patient is an expert multi-discipline approach to each
individual problem.
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